Dimitri P Mikhailidis
Overview
Explore the profile of Dimitri P Mikhailidis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
909
Citations
12404
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Singh M, Kumar A, Khanna N, Laird J, Nicolaides A, Faa G, et al.
EClinicalMedicine
. 2024 Jun;
73:102660.
PMID: 38846068
Background: The field of precision medicine endeavors to transform the healthcare industry by advancing individualised strategies for diagnosis, treatment modalities, and predictive assessments. This is achieved by utilizing extensive multidimensional...
12.
Mukherjee D, Mikhailidis D
Curr Opin Cardiol
. 2024 Jun;
39(4):279.
PMID: 38832818
No abstract available.
13.
Manolis A, Manolis T, Mikhailidis D, Manolis A
Biomark Insights
. 2024 Jun;
19:11772719241257410.
PMID: 38827240
Lipid-lowering therapies, particularly non-statin regimens, are underutilized as ~2/3 of patients with atherosclerotic cardiovascular (CV) disease (CVD) are not optimally managed, and do not attain target low-density lipoprotein cholesterol (LDL-C)...
14.
Kokkorakis M, Muzurovic E, Volcansek S, Chakhtoura M, Hill M, Mikhailidis D, et al.
Pharmacol Rev
. 2024 May;
76(3):454-499.
PMID: 38697855
Steatotic liver disease (SLD) displays a dynamic and complex disease phenotype. Consequently, the metabolic dysfunction-associated steatotic liver disease (MASLD)/metabolic dysfunction-associated steatohepatitis (MASH) therapeutic pipeline is expanding rapidly and in multiple...
15.
Anagnostis P, Mikhailidis D, Blinc A, Jensterle M, Jezovnik M, Schernthaner G, et al.
Curr Vasc Pharmacol
. 2024 Feb;
22(2):153-154.
PMID: 38321894
No abstract available.
16.
Castillo M, Salgado-Canales D, Arrese M, Barrera F, Mikhailidis D
Curr Vasc Pharmacol
. 2024 Feb;
22(3):187-202.
PMID: 38321893
Background: The first-line treatment for non-alcoholic fatty liver disease (NAFLD) is lifestyle modification; this should accompany any pharmacological intervention. Intermittent fasting (IF) has shown benefits over metabolic and cardiovascular parameters....
17.
Antignani P, Jezovnik M, Blinc A, Mikhailidis D, Anagnostis P, Schernthaner G, et al.
Curr Vasc Pharmacol
. 2024 Jan;
22(2):88-94.
PMID: 38284694
Primary hyperparathyroidism (PHPT) is presented in various forms, including classic PHPT, characterised by increased parathyroid hormone (PTH) secretion, normohormonal PHPT, and normocalcaemic PHPT. Secondary hyperparathyroidism is characterised by increased PTH...
18.
Surma S, Mikhailidis D, Banach M
Eur Heart J
. 2024 Jan;
45(9):647-650.
PMID: 38190310
No abstract available.
19.
Osadnik T, Nowak D, Osadnik K, Gierlotka M, Windak A, Tomasik T, et al.
Cardiovasc Diabetol
. 2023 Nov;
22(1):323.
PMID: 38017465
Background: An obesity paradox has been described in relation to adverse clinical outcomes (e.g., mortality) with lower body mass index (BMI). Aims: We sought to evaluate the association between BMI...
20.
Pantea Stoian A, Bica I, Salmen T, Al Mahmeed W, Al-Rasadi K, Al-Alawi K, et al.
Diabetes Ther
. 2023 Nov;
15(1):297-299.
PMID: 37964156
No abstract available.